G. Veerman

2.3k total citations
52 papers, 1.9k citations indexed

About

G. Veerman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, G. Veerman has authored 52 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in G. Veerman's work include Lung Cancer Treatments and Mutations (26 papers), Colorectal Cancer Treatments and Studies (11 papers) and Cancer therapeutics and mechanisms (10 papers). G. Veerman is often cited by papers focused on Lung Cancer Treatments and Mutations (26 papers), Colorectal Cancer Treatments and Studies (11 papers) and Cancer therapeutics and mechanisms (10 papers). G. Veerman collaborates with scholars based in Netherlands, United States and Germany. G. Veerman's co-authors include Godefridus J. Peters, Andries M. Bergman, Catharina M. Kuiper, Boudewijn J.M. Braakhuis, Herbert M. Pinedo, C.J.A. van Moorsel, Ron H.J. Mathijssen, Veronique W.T. Ruiz van Haperen, Jan B. Vermorken and Pieter E. Postmus and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

G. Veerman

51 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Veerman Netherlands	20	1.1k	730	635	347	236	52	1.9k
Warren Chow United States	27	796 0.7×	950 1.3×	640 1.0×	301 0.9×	325 1.4×	111	2.3k
Stephen Shibata United States	28	1.2k 1.1×	601 0.8×	433 0.7×	545 1.6×	226 1.0×	84	2.2k
G. Deplanque France	23	1.3k 1.2×	812 1.1×	633 1.0×	225 0.6×	542 2.3×	77	2.3k
Aristidis Polyzos Greece	24	1.3k 1.2×	481 0.7×	718 1.1×	275 0.8×	366 1.6×	67	2.4k
Randeep Sangha Canada	23	1.3k 1.2×	542 0.7×	590 0.9×	376 1.1×	250 1.1×	72	2.3k
Michael Millward Australia	25	1.7k 1.6×	1.1k 1.6×	1.1k 1.8×	331 1.0×	331 1.4×	43	2.9k
David Rinaldi United States	19	1.3k 1.2×	867 1.2×	542 0.9×	302 0.9×	131 0.6×	38	1.9k
Ioannis A. Voutsadakis Canada	27	1.2k 1.1×	474 0.6×	914 1.4×	208 0.6×	639 2.7×	161	2.3k
Ki Y. Chung United States	20	1.6k 1.5×	702 1.0×	617 1.0×	267 0.8×	208 0.9×	62	2.4k
Samir D. Undevia United States	21	1.3k 1.2×	809 1.1×	1.1k 1.7×	195 0.6×	186 0.8×	49	2.4k

Countries citing papers authored by G. Veerman

Since Specialization

Citations

This map shows the geographic impact of G. Veerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Veerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Veerman more than expected).

Fields of papers citing papers by G. Veerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Veerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Veerman. The network helps show where G. Veerman may publish in the future.

Co-authorship network of co-authors of G. Veerman

This figure shows the co-authorship network connecting the top 25 collaborators of G. Veerman. A scholar is included among the top collaborators of G. Veerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Veerman. G. Veerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Koch, Birgit C. P., et al.. (2024). Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis. Biomedicine & Pharmacotherapy. 179. 117341–117341.

Veerman, G., J. G. Coen van Hasselt, Hendrikus J. Dubbink, et al.. (2024). Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib. CPT Pharmacometrics & Systems Pharmacology. 13(4). 612–623. 4 indexed citations

Paats, Marthe S., Idris Bahce, Sander Croes, et al.. (2024). Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC. Journal of Thoracic Oncology. 20(4). 475–486. 1 indexed citations

Veerman, G., René J. Boosman, Ron H.J. Mathijssen, et al.. (2024). Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC. JTO Clinical and Research Reports. 5(4). 100656–100656. 2 indexed citations

Mohseni, Mostafa, G. Veerman, Marthe S. Paats, et al.. (2023). Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer. Journal of Thoracic Oncology. 18(8). 1017–1030. 17 indexed citations

Veerman, G., Marthe S. Paats, Vivianne C. G. Tjan‐Heijnen, et al.. (2023). Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer. International Journal of Cancer. 154(2). 332–342. 7 indexed citations

Veerman, G., et al.. (2023). Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients. Biomedicine & Pharmacotherapy. 163. 114823–114823. 5 indexed citations

Hoop, Esther Oomen‐de, Peter de Bruijn, Marthe S. Paats, et al.. (2023). Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial. Journal of the National Comprehensive Cancer Network. 21(6). 645–651.e1. 3 indexed citations

Veerman, G., René J. Boosman, Esther Oomen‐de Hoop, et al.. (2023). Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. EClinicalMedicine. 59. 101955–101955. 7 indexed citations

10.

Veerman, G., H. Carlijne Hassing, Marthe S. Paats, et al.. (2023). Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer. JACC CardioOncology. 5(1). 102–113. 13 indexed citations

11.

Veerman, G., Stijn L.W. Koolen, Jelle Miedema, et al.. (2022). The influence of green tea extract on nintedanib’s bioavailability in patients with pulmonary fibrosis. Biomedicine & Pharmacotherapy. 151. 113101–113101. 16 indexed citations

12.

Veerman, G., Peter de Bruijn, Anne‐Marie C. Dingemans, Ron H.J. Mathijssen, & Stijn L.W. Koolen. (2020). To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 193. 113733–113733. 10 indexed citations

13.

Wilt, C.L. van der, Harold H.J. Backus, Kees Smid, et al.. (2001). Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.. Data Archiving and Networked Services (DANS). 61(9). 3675–81. 56 indexed citations

14.

Moorsel, C.J.A. van, Herbert M. Pinedo, G. Veerman, et al.. (1999). Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing mice. European Journal of Cancer. 35(5). 808–814. 64 indexed citations

15.

Moorsel, C.J.A. van, Judith R. Kroep, Herbert M. Pinedo, et al.. (1999). Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Annals of Oncology. 10(4). 441–448. 76 indexed citations

16.

Smitskamp-Wilms, Evelien, Herbert M. Pinedo, G. Veerman, Veronique W.T. Ruiz van Haperen, & Godefridus J. Peters. (1998). Postconfluent multilayered cell line cultures for selective screening of gemcitabine. European Journal of Cancer. 34(6). 921–926. 30 indexed citations

17.

Moorsel, C.J.A. van, G. Veerman, J. B. Vermorken, et al.. (1998). Mechanisms of Synergism Between Gemcitabine and Cisplatin. Advances in experimental medicine and biology. 431. 581–585. 15 indexed citations

18.

Haperen, Veronique W.T. Ruiz van, et al.. (1998). Induction of in Vivo Resistance Against Gemcitabine (dFdC,2′,2′-Difluoro-Deoxycytidine). Advances in experimental medicine and biology. 431. 637–640. 9 indexed citations

19.

Boos, Joachim, et al.. (1998). Augmentation of 1-β-d-Arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs. European Journal of Cancer. 34(6). 895–901. 12 indexed citations

20.

Wilt, C.L. van der, Kees Smid, G. Veerman, & Godefridus J. Peters. (1998). The Role of Thymidine Kinase Activity in Murine Colon Tumours Treated with 5-Fluorouracil. Advances in experimental medicine and biology. 431. 653–656. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact